Obsessive-compulsive spectrum disorders: A review of the evidence-based treatments

Canadian Journal of Psychiatry

Volumn 54, Issue 5, 2009, Pages 331-343

  Ravindran, Arun V ^a,b   Da Silva, Tricia L ^b   Ravindran, Lakshmi N ^e   Richter, Margaret A ^a,c   Rector, Neil A ^a,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d Sunnybrook Health Sciences Centre   (Canada)

^e Centre for Addiction and Mental Health ^*

Author keywords

Atypical antipsychotics; Cognitive behavioural therapy; Obsessive compulsive disorder; Obsessive compulsive spectrum disorders; Pharmacotherapy; Psychotherapy; Serotonin reuptake inhibitors

Indexed keywords

ACETYLCYSTEINE; AMFEBUTAMONE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NALMEFENE; NALTREXONE; NEFAZODONE; OLANZAPINE; OPIATE ANTAGONIST; PAROXETINE; PLACEBO; SERTRALINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

BODY DYSMORPHIC DISORDER; CLINICAL TRIAL; COGNITIVE THERAPY; COMPULSION; DRUG EFFICACY; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; HABIT; HORMONE SUBSTITUTION; HUMAN; HYPOCHONDRIASIS; IMPULSIVENESS; KLEPTOMANIA; LOW DRUG DOSE; MORBIDITY; OBSESSIVE COMPULSIVE DISORDER; PATHOLOGICAL GAMBLING; REVIEW; SHORT COURSE THERAPY; TREATMENT DURATION; TRICHOTILLOMANIA; UNSPECIFIED SIDE EFFECT;

EID: 66349113850     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370905400507     Document Type: Review

References (166)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington (DC): APA; 2000.
2. Hollander E. Obsessive-compulsive-related disorders. Washington (DC): American Psychiatric Press; 1993.
3. Hollander E. Treatment of obsessive-compulsive spectrum disorders with SSRIs. Br J Psychiatry. 1998;173(Suppl 35):7-12. (Pubitemid 28368345)
4. Rasmussen SA. Obsessive-compulsive spectrum disorders. J Clin Psychiatry. 1994;55:89-91.
5. Cohen LS, Stein DJ, Simeon D, et al. Clinical profile, comorbidity, and treatment history in 123 hair pullers: a survey study. J Clin Psychiatry. 1995;56:319-326.
6. Swedo SE, Leonard HL. Trichotillomania. An obsessive compulsive spectrum disorder? Psychiatr Clin North Am. 1992;15:777-790.
7. Phillips KA, McElroy SL, Keck PE, et al. Body dysmorphic disorder: thirty cases of imagined ugliness. Am J Psychiatry. 1993;150:302-308. (Pubitemid 23046519)
8. Zimmerman M, Matia JI. Body dysmorphic disorder in psychiatric outpatients: recognition, prevalence, comorbidity, demographic, and clinical correlates. Comp Psychiatry. 1998;39:265-270. (Pubitemid 28426049)
9. Fallon BA, Rasmussen SA, Liebowitz MR. Hypochondriasis. In: Hollander E, editor. Obsessive-compulsive related disorders. Washington (DC): American Psychiatric Press; 1993. p 71-92.
10. Barsky AJ, Wyshak G, Klerman GL. Psychiatric comorbidity in DSM-III-R hypochondriasis. Arch Gen Psychiatry. 1992;49:101-108.
11. Arnold LM, McElroy SL, Mutasim DF, et al. Characteristics of 34 adults with psychogenic excoriation. J Clin Psychiatry. 1998;59:509-514. (Pubitemid 28492414)
12. Wilhelm S, Keuthen NJ, Deckersbauch T, et al. Self-injurious skin picking: clinical characteristics and comorbidity. J Clin Psychiatry. 1999;60:454-459. (Pubitemid 29369801)
13. Linden RD, Pope HG Jr, Jonas JM. Pathological gambling and major affective disorder: preliminary findings. J Clin Psychiatry. 1986;47:201-203. (Pubitemid 16109759)
14. Hollander E, Benzaquen SD. The obsessive-compulsive spectrum disorder. In: den Boer JA, Westenberg HGM, editors. Focus on obsessive compulsive spectrum disorders. Amsterdam (NL): Syn-Thesis Publishers; 1997. p 33-44.
15. Pauls DL, Alsobrook JP, Goodman WK, et al. A family study of obsessive compulsive disorder. Am J Psychiatry. 1995;152:76-84.
16. Lenane MC, Swedo SE, Rapoport JL, et al. Rates of obsessive compulsive disorder in first degree relatives of patients with trichotillomania: a research note. J Child Psychol Psychiatry. 1992;33:925-933.
17. McElroy SL, Pope HG, Hudson JI, et al. Kleptomania: a report of 20 cases. Am J Psychiatry. 1991;148:652-657.
18. Hollander E, Wong CM. Obsessive-compulsive spectrum disorders. J Clin Psychiatry. 1995;56(Suppl 4):3-6.
19. Linnoila M, Virkunen M, Scheinin M, et al. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci. 1983;33:2609-2614. (Pubitemid 14203851)
20. Leckman JF, Goodman WK, Anderson GM, et al. Cerebrospinal fluid biogenic amines in obsessive-compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology. 1995;12:73-86.
21. Bergh C, Eklund T, Sodersten P, et al. Altered dopamine function in pathological gambling. Psychol Med 1997;27:473-475. (Pubitemid 27139979)
22. Stein DJ, Hollander E. Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry. 1992;53:123-126.
23. Stein DJ, Bouwer C, Hawkridge S, et al. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry. 1997;58:119-122. (Pubitemid 27149253)
24. Van Ameringen M, Mancini, C, Oakman, JM, et al. The potential role of haloperidol in the treatment of trichotillomania. J Affect Disord. 1999;56:219-226. (Pubitemid 30058226)
25. Moreno I, Saiz-Ruiz J, Lopez-Ibor Aliño JJ. Serotonin and gambling dependence. Human Psychopharmacol. 1991;6:S9-S12.
26. Roy A, Adinoff B, Roehrick L, et al. Pathological gambling: a psychobiological study. Arch Gen Psychiatry. 1988;45:369-373. (Pubitemid 18124331)
27. Roy A, De Jong, J, Linnoila, M. Extraversion in pathological gamblers. Correlates with indexes of noradrenergic function. Arch Gen Psychiatry. 1989;46:679-681.
28. Phillips KA. The obsessive-compulsive spectrum: promises and pitfalls. In: Maj M, Sartorius N, Okasha A, et al, editors. Obsessive-compulsive disorder. Chichester (UK): John Wiley and Sons Ltd; 2000. p 225-227.
29. Black DW. The obsessive-compulsive spectrum: fact or fancy? In: Maj M, Sartorius N, Okasha A, et al, editors. Obsessive-compulsive disorder. Chichester (UK): John Wiley and Sons Ltd; 2000. p 233-235.
30. McElroy SL, Pope HG Jr, Keck PE Jr, et al. Are impulse control disorders related to bipolar disorder? Compr Psychiatry. 1996;37:229-240.
31. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005:7(Suppl 3):5-69. (Pubitemid 41065248)
32. Phillips KA, McElroy SL. Insight, overvalued ideation, and delusional thinking in body dysmorphic disorder: theoretical and treatment implications. J Nerv Ment Dis. 1993;181:699-702. (Pubitemid 24259665)
33. Veale D, Boocock A, Gournay K, et al. Body dysmorphic disorder: a survey of fifty cases. Br J Psychiatry. 1996;169:196-201. (Pubitemid 126735162)
34. Phillips KA, Gunderson CG, Mallya G, et al. A comparison study of body dysmorphic disorder and obsessive-compulsive disorder. J Clin Psychiatry. 1998;59:568-575. (Pubitemid 28555416)
35. Rich N, Rosen JC, Orosan PG. Prevalence of body dysmorphic disorder in non-clinical populations. Presented at the 26th annual convention of the Association for the Advancement of Behavior Therapy; 1992 November 2; Boston (MA).
36. Neziroglu F, Hsia C, Yaryura-Tobias JA. Behavioral, cognitive, and family therapy for obsessive-compulsive and related disorders. Psychiatr Clin North Am. 2000;23:657-670. (Pubitemid 30666513)
37. Veale D, Gournay K, Dryden W, et al. Body dysmorphic disorder: a cognitive behavioural model and pilot randomised controlled trial. Behav Res Ther. 1996;34:717-729. (Pubitemid 26356517)
38. Phillips KA, McElroy SL, Keck PE Jr, et al. A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases. Psychopharmacol Bull. 1994;30:179-186. (Pubitemid 24331384)
39. Phillips KA, McElroy SL, Gunderson CG, et al. Body dysmorphic disorder: data on imagined ugliness. Presented at the 147th annual meeting of the American Psychiatric Association; 1994 May 22: Philadelphia (PA).
40. Hollander E, Cohen LJ, Simeon D. Body dysmorphic disorder. Psychiatr Ann. 1993;23:359-644.
41. Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 2002;59:381-388. (Pubitemid 34275257)
42. Phillips KA, Rasmussen SA. Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: a placebo-controlled study. Psychosomatics. 2004;45:438-444. (Pubitemid 39166917)
43. Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 1998;59:165-171. (Pubitemid 28208330)
44. Perugi G, Giannotti D, Di Vaio S, et al. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol. 1996;11:247-254. (Pubitemid 27049289)
45. Hollander E, Allen A, Kwon J, et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999;56:1033-1039. (Pubitemid 29526387)
46. Phillips KA. An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol. 2006;21:177-179. (Pubitemid 43740309)
47. Phillips KA, Najjar F. An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry. 2003;64:715-720. (Pubitemid 36750151)
48. Phillips KA, Pagano ME, Menard W. Pharmacotherapy for body dysmorphic disorder: treatment received and illness severity. Ann Clin Psychiatry. 2006;18:251-257. (Pubitemid 44949904)
49. Rosen J. The nature of body dysmorphic disorder and treatment with cognitive behavior therapy. Cogn Behav Pract. 1995;2:143-166.
50. McKay D, Todaro J, Neziroglu F, et al. Body dysmorphic disorder: a preliminary evaluation of treatment and maintenance using exposure with response prevention. Behav Res Ther. 1997;35:67-70. (Pubitemid 27026168)
51. Rosen JC, Reiter J, Orosan P. Cognitive-behavioral body image therapy for body dysmorphic disorder. J Consult Clin Psychol. 1995;63:263-269.
52. Saxena S, Winograd A, Dunkin JJ, et al. A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder. J Clin Psychiatry. 2001;62:67-72. (Pubitemid 32154326)
53. Fallon BA, Liebowitz MR, Salmon E, et al. Fluoxetine for hypochondriacal patients without major depression. J Clin Psychopharmacol. 1993;13:438-441. (Pubitemid 24026106)
54. Greeven A, van Balkom AJ, Visser S, et al. Cognitive behavior therapy and paroxetine in the treatment of hypochondriasis: a randomized controlled trial. Am J Psychiatry. 2007;164:91-99. (Pubitemid 46154786)
55. Fallon BA, Quereshi AI, Schneier FR, et al. An open trial of fluvoxamine for hypochondriasis. Psychosomatics. 2003;44:298-303. (Pubitemid 36750536)
56. Pilkowsky I. The response to treatment in hypochondriacal disorders. Aust N Z J Psychiatry. 1968;2:88-94.
57. Thomson A, Page L. Psychotherapies for hypochondriasis. Cochrane Database Syst Rev. 2007;4:CD006520.
58. Warwick H, Clark D, Salkovskis P. A controlled trial of cognitive-behavioural treatment of hypochondriasis. Br J Psychiatry. 1996;169:189-195 (Pubitemid 126735161)
59. Barsky AJ, Ahern DK. Cognitive behavior therapy for hypochondriasis: a randomized controlled trial. JAMA. 2004;291:1464-1470. (Pubitemid 38543737)
60. Clark DM, Salkovskis PM, Hackmann A, et al. Two psychological treatments for hypochondriasis: a randomized controlled trial. Br J Psychiatry. 1998;173:218-225. (Pubitemid 28407454)
61. Visser S, Bouman TK. The treatment of hypochondriasis: exposure plus response prevention vs cognitive therapy. Behav Res Ther. 2001;39:423-442. (Pubitemid 32141145)
62. Kellner R. The prognosis of treated hypochondriasis: a clinical study. Acta Psychiatr Scand. 1983;67:69-79. (Pubitemid 13192008)
63. Fava GA, Grandi S, Rafanelli C, et al. Explanatory therapy in hypochondriasis. J Clin Psychiatry. 2000;61:317-322. (Pubitemid 30305380)
64. Bouman TK. A community-based psychoeducational group approach to hypochondriasis. Psychother Psychosom. 2002;71:326-332. (Pubitemid 36151508)
65. Christenson GA, Pyle RL, Mitchell JE. Estimated lifetime prevalence of trichotillomania in college students. J Clin Psychiatry. 1991;52:415-417.
66. Rothbaum BO, Shaw L, Morris R, et al. Prevalence of trichotillomania in a college freshman population. J Clin Psychiatry. 1993;54:73. (Pubitemid 23078216)
67. Swedo S, Leonard H, Lenane M, et al. Trichotillomania: a profile of the disorder from infancy through adulthood. Int Pediatr. 1992;7:144-150.
68. Winchel RM, Jones JS, Stanley B, et al. Clinical characteristics of trichotillomania and its response to fluoxetine. J Clin Psychiatry. 1992;53:304-308.
69. van Minnen A, Hoogduin KA, Keijsers GP, et al. Treatment of trichotillomania with behavioural therapy or fluoxetine: a randomized, waiting-list controlled study. Arch Gen Psychiatry. 2003;60:517-522. (Pubitemid 36539061)
70. Christenson GA, MacKenzie TB, Mitchell JE, et al. A placebo-controlled double-blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry. 1991;148:1566-1571.
71. Streichenwein SM, Thornby JI. A long-term, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. Am J Psychiatry. 1995;152:1192-1196.
72. Stanley MA, Breckenridge JK, Swann AC. Fluvoxamine treatment of trichotillomania. J Clin Psychopharmacol. 1997;17:278-283. (Pubitemid 27312426)
73. Dougherty DD, Loh R, Jenike MA, et al. Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both? J Clin Psychiatry. 2006;67:1086-1092. (Pubitemid 44230880)
74. Gadde KM, Ryan Wagner H, Connor KM, et al. Escitalopram treatment of trichotillomania. Int Clin Psychopharmacol. 2007;22:39-42. (Pubitemid 44950766)
75. Swedo SE, Leonard HL, Rapoport JL, et al. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med. 1989;321:497-501. (Pubitemid 19203873)
76. Ninan PT, Rothbaum BO, Marsteller FA, et al. A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. J Clin Psychiatry. 2000;61:47-50. (Pubitemid 30104384)
77. Bloch MH, Landeros-Weisenberger A, Dombrowski P, et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Biol Psychiatry. 2007;62:839-846. (Pubitemid 47488227)
78. Stewart RS, Nejtek VA. An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania. J Clin Psychiatry. 2003;64:49-52. (Pubitemid 36182229)
79. Christenson GA, Crow SJ, MacKenzie TB, et al. A placebo controlled double-blind study of naltrexone for trichotillomania. Poster presented at the American Psychiatric Association Annual Meeting; 1994 May; Philadelphia (PA).
80. Lochner C, Seedat S, Niehaus DJ, et al. Topiramate in the treatment of trichotillomania: an open-label pilot study. Int Clin Psychopharmacol. 2006;21:255-259. (Pubitemid 44162476)
81. Azrin NH, Nunn RG, Frantz SE. Treatment of hair-pulling (trichotillomania): a comparative study of habit reversal and negative practice training. J Behav Ther Exp Psychiatry. 1980;11:13-20. (Pubitemid 10050477)
82. Woods DW, Wetterneck CT, Flessner CA. A controlled evaluation of acceptance and commitment therapy plus habit reversal for trichotillomania. Behav Res Ther. 2006;44:639-656.
83. Diefenbach GJ, Tolin DF, Hannan S, et al. Group treatment for trichotillomania. Behav Ther. 2006;37:353-363.
84. Keijsers GP, van Minnen A, Hoogduin CA, et al. Behavioural treatment of trichotillomania: two-year follow-up results. Behav Res Ther. 2006;44:359-370. (Pubitemid 43163110)
85. Rothbaum BO. The behavioral treatment of trichotillomania. Behav Psychother. 1992;20:85-89.
86. Gluhoski VL. A cognitive approach for treating trichotillomania. J Psychother Pract Res. 1995;4:277-285.
87. Tolin DF, Franklin ME, Diefenbach GJ, et al. Pediatric trichotillomania: descriptive psychopathology and an open trial of cognitive behavioral therapy. Cogn Behav Ther. 2007;36:129-144. (Pubitemid 47604685)
88. Lorenz VC, Yaffee RA. Pathological gambling: psychosomatic, emotional and marital difficulties as reported by the gambler. J Gambl Behav. 1986;2:40-49.
89. Berg C, Kuhlhorn E. Social, psychological, and physical consequences of pathological gambling in Sweden. J Gambl Stud. 1994;10:275-285.
90. National Council on Problem Gambling. National Council on Problem Gambling Research and Public Policy Committees: problem and pathological gambling in America: the national picture. Columbia (MD): National Council on Problem Gambling; 1997.
91. Crockford DN, el-Guebaly N. Psychiatric comorbidity in pathological gambling: a critical review. Can J Psychiatry. 1998;43:43-50. (Pubitemid 28125128)
92. Lesieur HR, Klein R. Gambling and pathological gambling among high school students. Addict Behav. 1987;12:129-135. (Pubitemid 17116772)
93. Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry. 2002;63:44-48. (Pubitemid 34113486)
94. Grant JE, Potenza MN. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol. 2006;21:203-209. (Pubitemid 43740297)
95. Black DW, Shaw M, Forbush KT, et al. An open-label trial of escitalopram in the treatment of pathological gambling. Clin Neuropharmacol. 2007;30:206-212. (Pubitemid 47356717)
96. Kim SW, Grant JE, Adson DE, et al. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry. 2002;63:501-507. (Pubitemid 34680358)
97. Ravindran A, Telner J, Bhatla R, et al. Treating pathological gambling with cognitive behaviour therapy and paroxetine: treatment response, remission and predictors. Paper presented at the Canadian Psychiatric Association Annual Meeting; 2006 November; Toronto (ON).
98. Saiz-Ruiz J, Blanco C, Ibanez A, et al. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry. 2005;66:28-33.
99. Hollander E, DeCaria C, Mari E, et al. Short-term single-blind fluvoxamine treatment of pathological gambling. Am J Psychiatry. 1998;155:1781-1783. (Pubitemid 28547509)
100. Hollander E, DeCaria CM, Finkell JN, et al. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry. 2000;47:813-817. (Pubitemid 30254054)
101. Blanco C, Petkova E, Ibáòez A, et al. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry. 2002;14:9-15. (Pubitemid 34538827)
102. Hollander E, Pallanti S, Allen A, et al. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry. 2005;162:137-145.
103. Pallanti S, Quercioli L, Sood E, et al. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry. 2002;63:559-564. (Pubitemid 34787319)
104. Grant JE, Kim SW. Effectiveness of pharmacotherapy for pathological gambling: a chart review. Ann Clin Psychiatry. 2002;14:155-161. (Pubitemid 36172564)
105. Kim SW, Grant JE. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol. 2001;16:285-289. (Pubitemid 32822448)
106. Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49:914-921. (Pubitemid 32493813)
107. Dannon PN, Lowengrub K, Musin E, et al. Sustained-released bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study. J Clin Psychopharmacol. 2005;25:593-596. (Pubitemid 41669057)
108. Black DW. An open-label trial of bupropion in the treatment of pathological gambling. J Clin Psychopharmacol. 2004;24:108-110. (Pubitemid 38134183)
109. Black DW, Arndt S, Coryell WH, et al. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. J Clin Psychopharmacol. 2007;27:143-150. (Pubitemid 46594929)
110. Dannon PN, Lowengrub K, Gonopolski Y, et al. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropsychopharmacol. 2005;28:6-10. (Pubitemid 40269711)
111. Pallanti S, Baldini Rossi N, Sood E, et al. Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. J Clin Psychiatry. 2002;63:1034-1039. (Pubitemid 35388064)
112. Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163:180-181. (Pubitemid 44480852)
113. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007;62:652-657. (Pubitemid 47314380)
114. Pallesen S, Molde H, Arnestad HM, et al. Outcome of pharmacological treatments of pathological gambling: a review and meta-analysis. J Clin Psychopharmacol. 2007;27:357-364. (Pubitemid 47075506)
115. McConaghy N, Armstrong MS, Blaszczynski A, et al. Controlled comparison of aversive therapy and imaginal desensitization in compulsive gambling. Br J Psychiatry. 1983;142:366-372. (Pubitemid 13164249)
116. McConaghy N, Blasczynski A, Frankova A. Comparison of imaginal desensitization with other behavioural treatments of pathological gambling. A two- to nine-year follow-up. Br J Psychiatry. 1991;159:390-393.
117. Echeburua E, Baez C, Fernandez-Montalvo J. Comparative effectiveness of three therapeutic modalities in the psychological treatment of pathological gambling. Behav Cogn Psychother. 1996;24:51-72. (Pubitemid 126447563)
118. Echeburua E, Fernandez-Montalvo J, Baez C. Relapse prevention in the treatment of slot-machine pathological gambling: long-term outcome. Behav Ther. 2000;31:351-364. (Pubitemid 32144220)
119. Ladouceur R, Sylvain C, Boutin C, et al. Cognitive treatment of pathological gambling. J Nerv Ment Dis. 2001;189:774-780. (Pubitemid 33095527)
120. Sylvain C, Ladouceur R, Boisvert JM. Cognitive and behavioral treatment of pathological gambling: a controlled study. J Consult Clin Psychol. 1997;65:727-732. (Pubitemid 27439064)
121. Dowling N, Smith D, Thomas T. Treatment of female pathological gambling: the efficacy of a cognitive-behavioural approach. J Gambl Stud. 2006;22:355-372.
122. Ladouceur R, Sylvain C, Boutin C, et al. Group therapy for pathological gamblers: a cognitive approach. Behav Res Ther. 2003;41:587-596. (Pubitemid 36438637)
123. Dowling N, Smith D, Thomas T. A comparison of individual and group cognitive-behavioural treatment for female pathological gambling. Behav Res Ther. 2007;45(9):2192-2202. Epub 2006 Dec 28. (Pubitemid 47210943)
124. Bados, A, Balaguer G, Saldana C. The efficacy of cognitive-behavioral therapy and the problem of drop-out. J Clin Psychol. 2007;63:585-592. (Pubitemid 47011957)
125. Melville KM, Casey LM, Kavanagh DJ. Psychological treatment dropout among pathological gamblers. Clin Psychol Rev. 2007;27:944-958. (Pubitemid 47603261)
126. Stewart RM, Brown RIF. An outcome study of Gamblers Anonymous. Br J Psychiatry. 1988;152:284-288. (Pubitemid 18122346)
127. Lester D. The treatment of compulsive gambling. Int J Addict. 1980;15:201-206. (Pubitemid 10105864)
128. Brown RIF. The effectiveness of Gamblers Anonymous. In: Eadington WR, editor. The gambling studies. Proceedings of the Sixth National Conference on Gambling and Risk Taking. Reno (NV): Bureau of Business and Economic Administration, University of Nevada; 1985.
129. Lesieur HR, Blume SB. Evaluation of patients treated for pathological gambling in a combined alcohol, substance abuse, and pathological gambling treatment unit using the Addiction Severity Index. Br J Addict. 1991;86:1017-1028.
130. Russo AM, Taber JI, McCormick RA, et al. An outcome study of an inpatient treatment program for pathological gamblers. Hosp Community Psychiatry. 1984;35:823-827. (Pubitemid 14038086)
131. Petry NM, Ammerman Y, Bohl J, et al. Cognitive-behavioral therapy for pathological gamblers. J Consult Clin Psychol. 2006;74:555-567. (Pubitemid 44128235)
132. Petry NM, Litt MD, Kadden R, et al. Do coping skills mediate the relationship between cognitive-behavioral therapy and reductions in gambling in pathological gamblers? Addiction. 2007;102:1280-1291.
133. Hodgins DC, Currie S, El-Guebaly N. Motivational enhancement and self-help treatments for problem gambling. J Consult Clin Psychol. 2001;69:50-57. (Pubitemid 32210053)
134. Hodgins DC, Currie S, El-Guebaly N, et al. Brief motivational treatment for problem gambling: a 24-month follow-up. Psychol Addict Behav. 2004;18:293-296. (Pubitemid 39305175)
135. Wulfert E, Blanchard EB, Freidenberg BM, et al. Retaining pathological gamblers in cognitive behavior therapy through motivational enhancement: a pilot study. Behav Modif. 2006;30:315-340.
136. McElroy SL, Keck PE, Pope HG, et al. Compulsive buying: a report of 20 cases. J Clin Psychiatry. 1994;55:242-248. (Pubitemid 24235836)
137. Black DW. Compulsive buying: a review. J Clin Psychiatry. 1996;57(Suppl 8):50-55. (Pubitemid 26282191)
138. Faber RJ, O'Guinn RJ. A clinical screener for compulsive buying. J Consum Res. 1992;19:459-469.
139. Koran LM, Bullock KD, Hartston HJ, et al. Citalopram treatment of compulsive shopping: an open-label study. J Clin Psychiatry. 2002;63:704-708.
140. Koran LM, Chuong HW, Bullock KD, et al. Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. J Clin Psychiatry. 2003;64:793-798. (Pubitemid 36897216)
141. Koran LM, Aboujaoude EN, Solvason B, et al. Escitalopram for compulsive buying disorder: a double-blind discontinuation study. J Clin Psychopharmacol. 2007;27:225-227. (Pubitemid 46594952)
142. Black DW, Monahan P, Gabel J. Fluvoxamine in the treatment of compulsive buying. J Clin Psychiatry. 1997;58:159-163. (Pubitemid 27199781)
143. Black DW, Gabel J, Hansen J, et al. A double-blind comparison of fluvoxamine versus placebo in the treatment of compulsive buying disorder. Ann Clin Psychiatry. 2000;12:205-211. (Pubitemid 32046314)
144. Ninan PT, McElroy SL, Kane CP, et al. Placebo-controlled study of fluvoxamine in the treatment of patients with compulsive buying. J Clin Psychopharmacol. 2000;20:362-366. (Pubitemid 30318367)
145. Black DW. Recognition and treatment of obsessive-compulsive spectrum disorders. In: Swinson RP, Antony MM, Rachman S, et al, editors. Obsessive-compulsive disorder: theory, research, and treatment. New York (NY): Guildford Publications Inc; 1998. p 426-457.
146. Mitchell JE, Burgard M, Faber R, et al. Cognitive behavioral therapy for compulsive buying disorder. Behav Res Ther. 2006;44:1859-1865. (Pubitemid 44540357)
147. Koran LK, Aboujaoude EN, Gamel NN. Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. J Clin Psychiatry. 2007;3:422-427. (Pubitemid 46506808)
148. Grant JE, Kim SW. An open-label study of naltrexone in the treatment of kleptomania. J Clin Psychiatry. 2002;63:349-355. (Pubitemid 34456364)
149. Grant JE. Outcome study of kleptomania patients treated with naltrexone: a chart review. Clin Neuropharmacol. 2005;28:11-14. (Pubitemid 40269712)
150. Stein DJ, Hollander E. Dermatology and conditions related to obsessive-compulsive disorder. J Am Acad Dermatol. 1992;26:237-242.
151. Phillips KA, Taub SL. Skin picking as a symptom of body dysmorphic disorder. Psychopharmacol Bull. 1995;31:279-288.
152. Simeon D, Stein DJ, Hollander E. Depersonalization disorder and self-injurious behavior. J Clin Psychiatry. 1995;56(Suppl 4):36-39.
153. Leonard HL, Lenane MC, Swedo SE, et al. A double-blind comparison of clomipramine and desipramine treatment of severe onychophagia (nail biting). Arch Gen Psychiatry. 1991;48:821-827.
154. Simeon D, Stein DJ, Gross S, et al. A double-blind trial of fluoxetine in pathologic skin picking. J Clin Psychiatry. 1997;58:341-347. (Pubitemid 27375461)
155. Bloch MR, Elliott M, Thompson H, et al. Fluoxetine in pathological skin-picking: open-label and double-blind results. Psychosomatics. 2001;42:314-319. (Pubitemid 32692104)
156. Arnold LM, Mutasim DF, Dwight MM, et al. An open clinical trial of fluvoxamine treatment of psychogenic excoriation. J Clin Psychopharmacol. 1999;19:15-18. (Pubitemid 29047326)
157. Kalivas J, Kalivas L, Gilman D, et al. Sertraline in the treatment of neurotic excoriations and related disorders. Arch Dermatol. 1996;132:589-590. (Pubitemid 26136341)
158. Keuthen NJ, Jameson M, Loh R, et al. Open-label escitalopram treatment for pathological gambling. Int Clin Psychopharmacol. 2007;22:268-274. (Pubitemid 47237545)
159. Grant JE, Odlaug BL, Kim SW. Lamotrigine treatment of pathologic skin picking: an open-label study. J Clin Psychiatry. 2007;68:1384-1391. (Pubitemid 47524518)
160. Silber KP, Haynes CE. Treating nailbiting: a comparative analysis of mild aversion and competing response therapies. Behav Res Ther. 1992;30:15-22.
161. Allen KW. Chronic nailbiting: a controlled comparison of competing response and mild aversion treatments. Behav Res Ther. 1996;34:269-272. (Pubitemid 26093221)
162. Twohig MP, Woods DW, Marcks BA, et al. Evaluating the efficacy of habit reversal: comparison with a placebo control. J Clin Psychiatry. 2003;64:40-48. (Pubitemid 36182228)
163. Teng EJ, Woods DW, Twohig MP. Habit reversal as a treatment for chronic skin picking: a pilot investigation. Behav Modif. 2006;30:411-422. (Pubitemid 43807410)
164. Frost GR, Steketee G, editors. Cognitive approaches to obsessions and compulsions: theory, assessment, and treatment. New York (NY): Elsevier Science; 2002.
165. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation of treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11:622-632. (Pubitemid 43989810)
166. Sareen J, Kirshner A, Lander M, et al. Do antipsychotics ameliorate or exacerbate obsessive-compulsive disorder symptoms? A systematic review. J Affect Disord. 2004;82:167-174. (Pubitemid 39370818)